Most Recent
The Sydney Opera House Trust has resolved a long-running dispute accusing a China trade group of committing flagrant copyright infringement by reproducing substantial portions of the iconic landmark's trade mark-protected sail design in its logo.
Swiss food and drink giant Nestle has resolved a lawsuit by a2 Milk over a trade mark for infant formula, agreeing to withdraw an application with IP Australia to register the mark, NAN A2.
KFC has failed to block Grill’d’s HFC trade mark, with a judge finding the marks are not deceptively similar and that Grill'd did not act in bad faith despite parodying the fast food giant in advertising for its 'Healthy Fried Chicken' products.
The High Court has found Victorian real estate agency Biggin & Scott did not authorise through "indifference" the theft of Campaigntrack’s source code by a software developer it hired to create a cloud-based real estate marketing platform.
The Fair Work Commission has awarded compensation to an intellectual property lawyer who was unfairly dismissed for browsing personal websites during a period in which he said he was too busy to attend to a client’s patent application.
Novartis unit Sandoz AG has filed an appeal after it was was barred from selling a generic version of top-selling blood clot drug Xarelto and failed to revoke two Bayer patents for the drug.
A judge has rejected McDonald's claim that Hungry Jack's Big Jack burger infringed its Big Mac trade mark, but found that Hungry Jack's misled consumers by boasting that its burger had 25 per cent more beef.
South Korean biosimilars company Samsung Bioepis has sued to invalidate two patents held by a German competitor for a pre-filled syringe to treat age-related eye diseases, as generic drug makers race for a piece of the lucrative eye drug market.
Plaintiff law firm Shine Lawyers has succeeded in narrowing the services an early learning services chain can register its 'Shine Advantage' trade mark for.
Novartis unit Sandoz AG has lost its bid to revoke Bayer’s patents for its top-selling blood clot drug Xarelto and has been barred from selling generic versions of the medication after a judge found the German pharma giant’s patents were valid.